Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone
Authors Hori H, Yamada K, Kamada D, Shibata Y, Katsuki A, Yoshimura R, Nakamura J
Received 29 December 2013
Accepted for publication 3 February 2014
Published 26 March 2014 Volume 2014:10 Pages 527—533
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Hikaru Hori, Kenji Yamada, Dan Kamada, Yuka Shibata, Asuka Katsuki, Reiji Yoshimura, Jun Nakamura
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
Background: This study aims to determine the effectiveness of blonanserin (BNS) on the cognitive and social functions of patients with schizophrenia compared with risperidone (RIS) during acute-phase (8-week) treatment.
Methods: A total of 39 schizophrenia inpatients were included in this study. The subjects received either BNS (N=20) or RIS (N=19), and the clinical responses were evaluated periodically. The concomitant use of mood stabilizers was not allowed. Efficacy was assessed with the Positive and Negative Syndrome Scale for schizophrenia. Cognition was assessed using the Brief Assessment of Cognition in Schizophrenia, Japanese-language version. Social function was assessed using the Life Assessment Scale for the Mentally Ill.
Results: For both groups, each assessment exhibited a decrease in the mean change from baseline on the Positive and Negative Syndrome Scale. The depression subscale was significantly improved in the BNS group compared with the RIS group at 8 weeks after administration. BNS improved verbal fluency and executive function (cognitive function) and daily living and work skills (social function). Compared with the RIS group, BNS was observed to improve daily living.
Conclusion: BNS may improve psychotic symptoms, cognitive function, and daily living in patients with acute-phase schizophrenia. BNS may be superior to RIS in the improvement of daily living.
Keywords: risperidone, blonanserin, schizophrenia, cognitive function, social function, acute-phase
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]